Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lung Neoplasms 2Glioma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Sarcoma 1Nervous System Neoplasms 1Nervous System Diseases 1Neoplasms 1Melanoma 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Brain Neoplasms 1Brain Diseases 1Astrocytoma 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Adjuvants, Immunologic × Clear all
NCT01290692 2023-07-03

Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

TVAX Biomedical

Phase 2 Completed
14 enrolled 11 charts
CNS

Astrocytoma, Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma, Neoplasms, Nervous System Diseases, Nervous System Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡